Literature DB >> 3856094

The association of LDL receptor activity, LDL cholesterol level, and clinical course in homozygous familial hypercholesterolemia.

D L Sprecher, J M Hoeg, E J Schaefer, L A Zech, R E Gregg, E Lakatos, H B Brewer.   

Abstract

Patients with homozygous familial hypercholesterolemia (FH), reveal a marked heterogeneity in plasma cholesterol levels, response to diet as well as drug treatment, and clinical course. Low-density lipoprotein (LDL) receptor activities were assessed by the rate of 14C-oleate cholesteryl ester biosynthesis in fibroblasts from 13 FH homozygotes in tissue culture. The receptor activity of the individual patients was highly correlated with initial pretreatment plasma cholesterol and LDL cholesterol levels (P less than .001, r = -0.89). In addition, the LDL receptor activity was positively correlated with the age of onset of angina based on the Cox model (P less than .035, likelihood ratio = 6.71). An association was also noted between LDL receptor activity and cholesterol reduction with drugs. These data provide direct evidence for the correlation between the heterogeneity of the LDL receptor and the expression of the clinical manifestations of homozygous FH. The determination of pretreatment plasma cholesterol level and LDL receptor activity in patients with homozygous FH provide useful parameters on which to base predictions of the clinical progression of cardiovascular disease. These parameters may also influence the selection of a program for diet and drug therapy. Patients with markedly elevated plasma cholesterol levels and very low LDL receptor activity should be considered to be candidates for multiple drug therapy, and portacaval shunt, and/or periodic plasma exchanges.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3856094     DOI: 10.1016/0026-0495(85)90015-0

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  11 in total

1.  Temporary amelioration of hyperlipidemia in low density lipoprotein receptor-deficient rabbits transplanted with genetically modified hepatocytes.

Authors:  J M Wilson; N R Chowdhury; M Grossman; R Wajsman; A Epstein; R C Mulligan; J R Chowdhury
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

2.  Fatal myocardial infarction at 4.5 years in a case of homozygous familial hypercholesterolaemia.

Authors:  Matthias Gautschi; Mladen Pavlovic; Jean-Marc Nuoffer
Journal:  JIMD Rep       Date:  2011-09-06

3.  Liver transplantation for treatment of cardiovascular disease: comparison with medication and plasma exchange in homozygous familial hypercholesterolemia.

Authors:  J M Hoeg; T E Starzl; H B Brewer
Journal:  Am J Cardiol       Date:  1987-03-01       Impact factor: 2.778

4.  Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange.

Authors:  G R Thompson; J P Miller; J L Breslow
Journal:  Br Med J (Clin Res Ed)       Date:  1985-12-14

Review 5.  Clinical consequences of hyperlipidaemia.

Authors:  G R Thompson
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

Review 6.  Statins in children: what do we know and what do we need to do?

Authors:  D M Black
Journal:  Curr Atheroscler Rep       Date:  2001-01       Impact factor: 5.113

7.  Response to drugs and diet in a compound heterozygote for familial hypercholesterolaemia.

Authors:  V Gudnason; D P Muller; J K Lloyd; S E Humphries
Journal:  Arch Dis Child       Date:  1995-12       Impact factor: 3.791

8.  Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia.

Authors:  Sadik H Kassim; Hui Li; Peter Bell; Suryanarayan Somanathan; William Lagor; Frank Jacobs; Jeffrey Billheimer; James M Wilson; Daniel J Rader
Journal:  Hum Gene Ther       Date:  2012-11-14       Impact factor: 5.695

9.  Metabolism of low-density lipoproteins by cultured hepatocytes from normal and homozygous familial hypercholesterolemic subjects.

Authors:  J M Hoeg; S B Edge; S J Demosky; T E Starzl; T Triche; R E Gregg; H B Brewer
Journal:  Biochim Biophys Acta       Date:  1986-05-21

10.  In search of a genetic explanation for LDLc variability in an FH family: common SNPs and a rare mutation in MTTP explain only part of LDL variability in an FH family.

Authors:  Michael Winther; Shoshi Shpitzen; Or Yaacov; Jakob Landau; Limor Oren; Linda Foroozan-Rosenberg; Naama Lev Cohain; Daniel Schurr; Vardiela Meiner; Auryan Szalat; Shai Carmi; Michael R Hayden; Eran Leitersdorf; Ronen Durst
Journal:  J Lipid Res       Date:  2019-08-06       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.